HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients

Kidney International

Volumn 61, Issue 1, 2002, Pages 297-304

  Seliger, Stephen L ^a,b,c   Weiss, Noel S ^a,b,c   Gillen, Daniel L ^a,b,c   Kestenbaum, Bryan ^a,b,c   Ball, Adrianne ^a,b,c   Sherrard, Donald J ^a,b,c   Stehman Breen, Catherine O ^a,b,c  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Veterans Administration   (United States)

Author keywords

Blood pressure; Cardiovascular disease; Dialysis; End stage renal disease; Hypercholesterolemia; Lipoprotein; USRDS Wave 2

Indexed keywords

FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DATA ANALYSIS; DEATH; DIALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG USE; ETHNIC DIFFERENCE; FEMALE; FOLLOW UP; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; SEX DIFFERENCE; TREATMENT OUTCOME;

EID: 0036147221     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2002.00109.x     Document Type: Article

References (31)

1. Accelerated atherosclerosis in prolonged maintenance hemodialysis
2. Clinical epidemiology of cardiovascular disease in chronic renal disease
3. Prevalence of serum lipid abnormalities in chronic hemodialysis
4. Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis
5. Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients
6. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
7. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
8. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
9. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels
10. Effect of simvastatin on the dyslipoproteinemia in CAPD patients
11. Effect of simvastatin on the lipid profile of hemodialysis patients
12. Reduction of intermediate density lipoprotein by pravastatin in hemo- and peritoneal dialysis patients
13. Effects of lipid-lowering drugs on intermediate-density lipoprotein in uremic patients
14. Effects of simvastatin and enalapril on serum lipoprotein concentrations and left ventricular mass in patients on dialysis
15. Effect of treatment with simvastatin on serum cholesteryl ester transfer in patients on dialysis
16. Effects of HMG-CoA reductase inhibitors in hypercholesterolemic patients on hemodialysis
17. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease
18. Serum lipids predict cardiac death in diabetic patients on maintenance hemodialysis
19. Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes predict coronary artery disease in hemodialysis patients
20. Hyperlipidemia in patients with chronic renal disease
21. Impaired metabolism of high density lipoprotein in uremic patients
22. Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness
23. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events
24. Action of atorvastatin in combined hyperlipidemia: Preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles
25. Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids
26. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults
27. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
28. Reassessing the cardiac risk profile in chronic hemodialysis patients: A hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors
29. Non-lipid-related effects of statins
30. Cause of death in patients with end-stage renal disease: Death certificates vs. registry reports